Infliximab as rescue therapy in severe steroid-resistant ulcerative colitis;Infliximab como terapia de rescate en colitis ulcerosa grave resistente al tratamiento corticoideo

Anales de Pediatria

Volumn 69, Issue 4, 2008, Pages 351-354

  Martin De Carpi J ^a,b   Vilar Escrigas, P ^a   Varea Calderon V ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

Infliximab; Steroid resistance; Ulcerative colitis

Indexed keywords

CYCLOSPORIN A; GENTAMICIN; INFLIXIMAB; MESALAZINE; METRONIDAZOLE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; DISEASE SEVERITY; DRUG EFFICACY; HORMONE RESISTANCE; HUMAN; REMISSION; SCHOOL CHILD; ULCERATIVE COLITIS;

EID: 54849422402     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13126560     Document Type: Article

References (20)

1. Turner D, Walsh CM, Benchimol EI, Mann EH, Thomas KE, Chow C, et al. Severe pediatric ulcerative colitis: Incidence, outcomes, and optimal timing for second-line therapy. Gut. 2008;57:331-8.
2. Hyams JS, Davis P, Lere T, Justinich CJ, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996;129:81-8.
3. Koivusalo A, Pakarinen, MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg. 2007;42:290-5.
4. Wewer V, Hesselfeldt P, Qvist N, Husby S, Paerregaard A. J-pouch ileoanal anastomosis in children and adolescents with ulcerative colitis: Functional outcome, satisfaction and impact on social life. J Pediatr Gastroenterol Nutr. 2005;40:189-93.
5. Castro M, Papadatou B, Ceraiatti E, Knafelz D, De Angelis P, Ferreti F, et al. Role of cyclosporin in preventing or delaying colectomy in children with severe ulcerative colitis. Langenbecks Arch Surg. 2007;392:161-4.
6. Barabino A, Torrente F, Castellano E, Gandullia P, Calvi A, Cucchiara S, et al. The use of ciclosporin in paediatric inflammatory bowel disease: An Italian experience. Aliment Pharmacol Ther. 2002;16:1503-7.
7. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1995;38:474-9.
8. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-81.
9. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study. Inflamm Bowel Dis. 2001;7:83-8.
10. Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-11.
11. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MGW, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905-10.
12. Turner D, Otley AR, Mack D, De Bruijne J, Uusoue K, Walter T, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): A prospective multicenter study. Gastroenterology. 2007;133:423-32.
13. Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2006;25:19-37.
14. Eidelwein AP, Cuffari C, Abadon V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-8.
15. Mamula P, Markowitz JE, Cohen LJ, Von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: Two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301.
16. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 2006;40:476-81.
17. Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;44:312-7.
18. Kashigawi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002;47:1334-41.
19. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-7.
20. Wewer V, Riis L, Vind I, Husby S, Munkholm P, Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr. 2006;42:40-5.